Purple Biotech Reports Q1 2024 Financial Results
Ticker: PPBT · Form: 6-K · Filed: May 21, 2024 · CIK: 1614744
Sentiment: neutral
Topics: financial-results, quarterly-report, pharmaceuticals
TL;DR
Purple Biotech dropped its Q1 2024 earnings report on May 21st.
AI Summary
Purple Biotech Ltd. announced its first quarter 2024 financial results on May 21, 2024. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with an update on Purple Biotech's financial performance for the first quarter of 2024, which is crucial for assessing the company's operational health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing with no new material events or significant financial changes disclosed.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the report
- Kitov Pharma Ltd. (company) — Former company name
- May 21, 2024 (date) — Date of press release and filing
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report Purple Biotech Ltd.'s first quarter 2024 financial results via an attached press release.
When were the first quarter 2024 financial results announced?
The first quarter 2024 financial results were announced on May 21, 2024.
What is Purple Biotech Ltd.'s former company name?
Purple Biotech Ltd.'s former company name was Kitov Pharma Ltd.
Where is Purple Biotech Ltd. located?
Purple Biotech Ltd. is located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Under which SEC Act is this filing made?
This filing is made under the Securities Exchange Act of 1934.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-05-21 07:40:11
Filing Documents
- ea0206609-6k_purplebio.htm (6-K) — 14KB
- ea020660901ex99-1_purplebio.htm (EX-99.1) — 114KB
- 0001213900-24-045373.txt ( ) — 129KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. May 21, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2